Comparable Outcomes after Nonmyeloablative Hematopoietic Cell Transplantation with Unrelated and Related Donors

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 12, 2007, Pages 1499-1507

  Mielcarek, Marco ^a,b   Storer, Barry E ^a,b   Sandmaier, Brenda M ^a,b   Sorror, Mohamed L ^a   Maloney, David G ^a,b   Petersdorf, Effie ^a,b   Martin, Paul J ^a,b   Storb, Rainer ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Hematologic malignancies; Nonmyeloablative; Related; Transplantation; Unrelated

Indexed keywords

CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR SELECTION; ENGRAFTMENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; WHOLE BODY RADIATION;

ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WASHINGTON;

EID: 36048965258     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.09.004     Document Type: Article

References (46)

1. Hurley C.K., Fernandez V.M., and Setterholm M. Maximizing optimal hematopoietic stem cell donor selection from registries of unrelated adult volunteers. Tissue Antigens 61 (2003) 415-424
2. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313 (1985) 765-771
3. Beatty P.G., Hansen J.A., Anasetti C., et al. Marrow transplantation from unrelated HLA-matched volunteer donors. Transplant Proc 21 (1989) 2993-2994
4. Ash R.C., Casper J.T., Chitambar C.R., et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 322 (1990) 485-494
5. Marks D.I., Cullis J.O., Ward K.N., et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med 119 (1993) 207-214
6. Schiller G., Feig S.A., Territo M., et al. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 88 (1994) 72-78
7. Nademanee A., Schmidt G.M., Parker P., et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 86 (1995) 1228-1234
8. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92 (1998) 3515-3520
9. Petersdorf E.W., Longton G.M., Anasetti C., et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 89 (1997) 1818-1823
10. Petersdorf E.W., Longton G.M., Anasetti C., et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, and DR identical unrelated donor marrow transplantation. Blood 86 (1995) 1606-1613
11. Speiser D.E., Tiercy J.M., Rufer N., et al. High-resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 87 (1996) 4455-4462
12. Horowitz M.M., Loberiza F.R., Bredeson C.N., et al. Transplant registries: guiding clinical decisions and improving outcomes. Oncology 15 (2001) 649-659
13. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
14. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
15. Sandmaier B.M., Maloney D.G., Gooley T., et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen. Blood 98 Part 1 (2001) 742a-743a
16. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 (2001) 3595-3599
17. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
18. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 104 (2004) 961-968
19. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99 (2002) 1071-1078
20. Hill G.R., Crawford J.M., Cooke K.R., et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
21. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
22. Cooke K.R., Hill G.R., Crawford J.M., et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 102 (1998) 1882-1891
23. Nestel F.P., Price K.S., Seemayer T.A., et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J Exp Med 175 (1992) 405-413
24. Xun C.Q., Thompson J.S., Jennings C.D., et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H2-incompatible transplanted SCID mice. Blood 83 (1994) 2360-2367
25. Colson Y.L., Lange J., Fowler K., et al. Mechanism for cotolerance in nonlethally conditioned mixed chimeras: negative selection of the Vβ T-cell receptor repertoire by both host and donor bone marrow-derived cells. Blood 88 (1996) 4601-4610
26. Manilay J.O., Pearson D.A., Sergio J.J., et al. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 66 (1998) 96-102
27. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102 (2003) 2021-2030
28. Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94 (1999) 3234-3241
29. Mielcarek M., Burroughs L., Leisenring W., et al. Prognostic relevance of "early-onset" graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation. Br J Haematol 129 (2005) 381-391
30. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
31. Couriel D.R., Saliba R.M., Giralt S., et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10 (2004) 178-185
32. Maris M.B., Sandmaier B.M., Storer B.E., et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 12 (2006) 454-465
33. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA- matched related donors. Blood 104 (2004) 1550-1558
34. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
35. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 11 (2007) 2744-2748
36. Prentice R.L., Kalbfleisch J.D., Peterson Jr. A.V., et al. The analysis of failure times in the presence of competing risks. Biometrics 34 (1978) 541-554
37. Makuch R.W. Adjusted survival curve estimation using covariates. J Chronic Dis 35 (1982) 437-443
38. Weisdorf D.J., Anasetti C., Antin J.H., et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99 (2002) 1971-1977
39. Parimon T., Au D.H., Martin P.J., et al. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 144 (2006) 407-414
40. Petersdorf E.W., Anasetti C., Martin P.J., et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104 (2004) 2976-2980
41. Szydlo R., Goldman J.M., Klein J.P., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15 (1997) 1767-1777
42. Moore J., Nivison-Smith I., Goh K., et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 13 (2007) 601-607
43. Hansen J.A., Gooley T.A., Martin P.J., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338 (1998) 962-968
44. Ottinger H.D., Ferencik S., Beelen D.W., et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood 102 (2003) 1131-1137
45. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24 (2006) 5695-5702
46. Kiehl M.G., Kraut L., Schwerdtfeger R., et al. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 22 (2004) 2816-2825